JPMorgan analyst Brian Cheng raised the firm’s price target on Revolution Medicines (RVMD) to $82 from $71 and keeps an Overweight rating on the shares. JPMorgan also added the shares to its Analyst Focus List as a growth idea. While the company’s Q3 report seems like a “non-event,” it is making strategic moves to position the entire portfolio to “win in the long run,: the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright
- Revolution Medicines Reports Q3 2025 Financial Results
- Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
- Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
- Revolution Medicines reiterates FY25 GAAP net loss guidance